

Public Health Institutes of the World

IANPHI

2011
Annual Meeting
Helsinki, Finland

NATIONAL INSTITUTE FOR HEALTH AND WELFARE


Israel's population

- 7,500,000 by the end of 2010
- Of them:
 - ◆ 76% Jews (5,700,000)
 - ◆ 20% Arabs (1,500,000)
 - ◆ 4% Others (300,000)




Cervical cancer Invasive tumors

- In 2009
 - ◆ ASR*/100,000 in Jews: 5.47
 - ◆ ASR*/100,000 in Arabs: 4.41
- Time trends 1991-2009 (19 y)
 - ◆ Stable (non-significant increase) in Jews and Arabs



International comparison

(Invasive tumors, 2008, ASR/100,000)



Relative survival (invasive tumors only)

Dx	% 5y survival
1990-1994	64
1995-1999	66
2000-2004	70

Lower than in the US and Australia;
Similar to some European countries (Finland)

Early detection

- National Health Insurance
 - 100% coverage, 4 HMOs
- Pap smear fully covered for
 - ◆ All women aged 35-54 (highest incidence) – 1x3y
 - ◆ High-risk groups (?)
- Utilization

KAP 2008-9: **ever** a pap smear; 35-54y old women

 - ◆ Jews – 63.4%
 - ◆ Arabs – 29.6%

Cervical cancer In-situ (CIN-III) tumors


- In 2009

- ◆ ASR*/100,000 in Jews: 19.42


- ◆ ASR*/100,000 in Arabs: 2.79

- Time trends 1991-2009 (19 y)

- ◆ A significant increase in Jews (+86%) and Arabs (+365%)




Natural progress



Cervical Cancer Trends

In-situ vs. invasive



HPV genotypes

Invasive cervical cancer

- Lancet Oncology 2010 (de Sanjose et al.) – 22,661 samples
 - ◆ HPV-DNA positive – 85%
 - ◆ Genotypes **16,18** (in those positive) – **71%**
 - SCC – 70%; Adenocarcinoma – 82%

HPV genotypes in Israel

- Largely unknown
 - ◆ Grisaru et al., 2008, pilot study

	Israel N=84 Colposcopy (% of those positive)	World N=22,661 Invasive cervical cancer (% of those positive)
HPV-16	41	61
HPV-18	14	10
HPV-39	22	2
HPV-52	19	3

A Dilemma

- In a country with low incidence of invasive cervical cancer
 - ◆ But increasing incidence of in-situ cervical cancer
- And where HPV main serotypes (re. cervical cancer) are largely unknown -
- **Should HPV vaccine be included in the national immunization program?**

Decision

- Based on
 - ◆ available scientific data
 - ◆ And cost-benefit analyses done for Israel
 - a positive value if dose \leq \$99
- In 2012, HPV vaccine will be included in the Israeli national immunization program
 - ◆ Girls aged 14y
- Additionally,
 - ◆ Re-consideration of the screening program
 - ◆ Study of HPV genotypes in Israel